Total pharma industry M&A deals in Q2 2019 worth $19.5bn were announced in the US, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 84.8% over the previous quarter and a drop of 52.9% when compared with the last four-quarter average of $41.79bn.

The US held a 17% share of the global pharma industry M&A deal value that totalled $114.8bn in Q2 2019.

In terms of deal activity, the US recorded 52 deals during Q2 2019, marking a drop of 7.1% over the previous quarter and a drop of 13.3% over the last four-quarter average.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The US pharma industry M&A deals in Q2 2019: Top deals

The top five pharma industry M&A deals accounted for 89.1% of the overall value during Q2 2019.

The combined value of the top five pharma industry M&A deals stood at $17.38bn, against the overall value of $19.5bn recorded for the quarter. The top announced pharma industry M&A deal tracked by GlobalData in Q2 2019 was Pfizer’s $11.4bn acquisition of Array BioPharma.

In second place was the $2.2bn acquisition of Peloton Therapeutics by Merck &Inc and in third place was Novartis‘ $1.58bn acquisition of IFM Tre.

The $1.2bn acquisition of Paragon Bioservices by Catalent and Vertex Pharmaceuticals‘ acquisition of Exonics Therapeutics for $1bn held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.